BLyS Inhibitors
1 drugsAbout BLyS
B Lymphocyte Stimulator (BLyS), also called BAFF, is a cytokine crucial for B cell survival, maturation, and antibody production. It binds to receptors on B cells, promoting their development and function within the immune system. As a key regulator of B cell activity, BLyS is a compelling target for drug development.
BLyS modulation offers a therapeutic avenue for autoimmune diseases with dysregulated B cell function; however, there is currently no genetic evidence directly linking BLyS to specific diseases. Targeting BLyS can help control B cell-mediated immune responses in various immunological disorders.
There is one FDA-approved drug, BENLYSTA (GSK), targeting BLyS in the immunology therapeutic area. BENLYSTA, an antibody, was first approved in 2011 and remains the only approved drug for this target.
Top BLyS Drugs
GSK is the only company with an approved drug targeting BLyS.
High market concentration indicates potential entry barriers; consider partnership or novel approach.
BLyS Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets BLyS, using antibody modality.
Explore alternative modalities like small molecules to differentiate from existing antibody therapies.
BLyS Clinical Trials 63 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on BLyS. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 13 | 9 | 1 | 3 | 90% |
| Phase 2 | 27 | 11 | 6 | 10 | 65% |
| Phase 3 | 13 | 10 | 0 | 3 | 100% |
| Phase 4 | 10 | 6 | 0 | 4 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved BLyS drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting BLyS. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
BLyS Drug Approval Timeline (2011 - 2011)
The first and only drug, BENLYSTA, was approved in 2011.
The approval timeline suggests a saturated market; new entrants need a differentiated value proposition.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 26 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on BLyS. A trial counts if an approved drug acting on BLyS is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.